ServiceNow trades at 26x forward earnings, near decade lows, with a 21% subscription revenue growth guide and a 97% renewal ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...